Calif. Biotech Firm Settles SEC's COVID-19 Blood Test Claims
A California biotech company and its CEO have agreed to settle a U.S. Securities and Exchange Commission suit alleging that they lied to investors about the development of a blood test...To view the full article, register now.
Already a subscriber? Click here to view full article